Pantuck Allan J, Zisman Amnon, Dorey Fredrick, Chao Debby H, Han Ken-Ryu, Said Jonathan, Gitlitz Barbara J, Figlin Robert A, Belldegrun Arie S
Department of Urology, University of California School of Medicine, Los Angeles, California, USA.
J Urol. 2003 Jun;169(6):2076-83. doi: 10.1097/01.ju.0000066130.27119.1c.
We better defined the benefits and morbidity of lymph node dissection in patients with localized renal cell carcinoma using the experience of patients treated at our institution.
A retrospective cohort study was performed with outcome assessment based on the chart review of demographic, clinical and pathological data in 1,087 patients with renal cell carcinoma treated at our institution. Patients with renal cell carcinoma who did not undergo nephrectomy as part of cancer treatment, those with bilateral disease and those for whom nodal status was unknown were not included in this study. A total of 900 patients meeting these criteria who underwent nephrectomy for unilateral renal cell carcinoma at our medical center form the principal study population.
Positive lymph nodes were associated with larger, higher grade, locally advanced primary tumors that were more commonly associated with sarcomatoid features. Positive nodes were 3 to 4 times more common in patients with metastatic disease and the majority of these patients could be identified preoperatively. The survival of patients with regional lymph node involvement only was identical to that of patients with distant metastatic disease only. Patients with regional nodes and distant metastases had significantly inferior survival to those with either condition alone. In node negative cases lymph node dissection can be performed with no additional morbidity but it confers no survival advantage. In node positive cases lymph node dissection can also be performed safely but it is associated with improved survival and a trend toward an improved response to immunotherapy.
Regional lymph node dissection is unnecessary in patients with clinically negative lymph nodes since it offers extremely limited staging information and no benefit in terms of decreasing disease recurrence or improving survival. In patients with positive lymph nodes lymph node dissection is associated with improved survival when it is performed in carefully selected patients undergoing cytoreductive nephrectomy and postoperative immunotherapy. When lymph nodes are present, they should be resected when technically feasible.
利用我院治疗患者的经验,进一步明确局限性肾细胞癌患者淋巴结清扫的益处及并发症。
进行一项回顾性队列研究,基于对我院治疗的1087例肾细胞癌患者的人口统计学、临床和病理数据进行图表回顾来评估结局。未将作为癌症治疗一部分未接受肾切除术的肾细胞癌患者、双侧疾病患者以及淋巴结状态未知的患者纳入本研究。共有900例符合这些标准且在我院医疗中心因单侧肾细胞癌接受肾切除术的患者构成主要研究人群。
阳性淋巴结与更大、更高分级、局部进展的原发性肿瘤相关,这些肿瘤更常伴有肉瘤样特征。阳性淋巴结在转移性疾病患者中常见3至4倍,且这些患者中的大多数可在术前识别。仅区域淋巴结受累患者的生存率与仅远处转移疾病患者的生存率相同。有区域淋巴结和远处转移的患者生存率明显低于单独患有这两种情况之一的患者。在淋巴结阴性的病例中,可进行淋巴结清扫且无额外并发症,但不具有生存优势。在淋巴结阳性的病例中,也可安全地进行淋巴结清扫,且与生存率提高及免疫治疗反应改善的趋势相关。
临床淋巴结阴性的患者无需进行区域淋巴结清扫,因为其提供的分期信息极为有限,且在降低疾病复发或提高生存率方面无益处。在淋巴结阳性的患者中,当对经过仔细选择的接受减瘤性肾切除术和术后免疫治疗的患者进行淋巴结清扫时,与生存率提高相关。当存在淋巴结时,在技术可行的情况下应予以切除。